TY - JOUR

T1 - Foresight in clinical proteomics

T2 - current status, ethical considerations, and future perspectives

AU - Mundt, Filip

AU - Albrechtsen, Nicolai J.Wewer

AU - Mann, Sebastian Porsdam

AU - Treit, Peter

AU - Ghodgaonkar-Steger, Medini

AU - O’Flaherty, Martina

AU - Raijmakers, Reinout

AU - Vizcaíno, Juan Antonio

AU - Heck, Albert J.R.

AU - Mann, Matthias

N1 - Publisher Copyright: Copyright: © 2023 Mundt F et al.

PY - 2023

Y1 - 2023

N2 - With the advent of robust and high-throughput mass spectrometric technologies and bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic and translational life sciences research. More than 95% of FDA-approved drugs currently target proteins, and most diagnostic tests are protein-based. The introduction of proteomics to the clinic, for instance to guide patient stratification and treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by the proteomics and medical communities. Consortium members of the H2020 European Union-funded proteomics initiative: European Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at the Core Technologies for Life Sciences (CTLS) conference to discuss the emerging role and implementation of proteomics in the clinic. The discussion, involving leaders in the field, focused on the current status, related challenges, and future efforts required to make proteomics a more mainstream technology for translational and clinical research. Here we report on that discussion and provide an expert update concerning the feasibility of clinical proteomics, the ethical implications of generating and analyzing large-scale proteomics clinical data, and recommendations to ensure both ethical and effective implementation in real-world applications.

AB - With the advent of robust and high-throughput mass spectrometric technologies and bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic and translational life sciences research. More than 95% of FDA-approved drugs currently target proteins, and most diagnostic tests are protein-based. The introduction of proteomics to the clinic, for instance to guide patient stratification and treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by the proteomics and medical communities. Consortium members of the H2020 European Union-funded proteomics initiative: European Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at the Core Technologies for Life Sciences (CTLS) conference to discuss the emerging role and implementation of proteomics in the clinic. The discussion, involving leaders in the field, focused on the current status, related challenges, and future efforts required to make proteomics a more mainstream technology for translational and clinical research. Here we report on that discussion and provide an expert update concerning the feasibility of clinical proteomics, the ethical implications of generating and analyzing large-scale proteomics clinical data, and recommendations to ensure both ethical and effective implementation in real-world applications.

KW - Clinical proteomics; clinical research; ethical challenges

U2 - 10.12688/openreseurope.15810.1

DO - 10.12688/openreseurope.15810.1

M3 - Letter

C2 - 37645494

AN - SCOPUS:85169124340

VL - 3

JO - Open Research Europe

JF - Open Research Europe

SN - 2732-5121

M1 - 59

ER -